Belgium Pharmaceuticals & Healthcare Report

Published 16 June 2015

  • 109 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Belgium Pharmaceuticals & Healthcare Report

BMI View: With structurally higher prices than many regional markets and quickly rising pharmaceutical consumption, Belgium will continue to present a high level of potential reward to drugmaker . Notably, a distinct lack of price transparency within the pharmaceutical value chain will combine with patient and prescriber bias towards patented drugs to hamper initiatives that seek to reduce public sector pharmaceutical reimbursement spending. However, an increasingly credible threat of domestic terrorism and the destabilising potential of Flemish separatism will weigh on the country's risk profile, increasing the costs and administrative burden borne by investors.

Headline Expenditure Projections

  • Pharmaceuticals: From EUR5.78bn (USD7.75bn) in 2014 to EUR5.80bn (USD6.38bn) in 2015; 0.24% in local currency terms and -17.7% in US dollar terms. Forecast revised upwards from previous quarter.

  • Healthcare: From EUR43.87bn (USD58.77bn) in 2014 to EUR44.96bn (USD49.46bn) 2015; +2.5% in local currency terms and -15.8% in US dollar terms. Forecast revised upwards from previous quarter.

Risk/Reward Index:

In BMI's Q315 Western European Risk/Reward Index, Belgium declines significantly in favour of more lucrative regional markets with a score of 68.0 out of 100, down from a Q215 score of 69.2. Weighed down by a deteriorating risks score, Belgium is ranked as the 9th most attractive pharmaceutical and healthcare market out of 15 in the region, relinquishing 6th place to Norway. Despite sustaining slightly above average reward scores, Belgium is markedly outperformed by the value growth potential and relative political stability characteristic of pharmaceutical markets such as Switzerland, the UK and France.,

Key Trends and Developments

  • In April 2015, the Belgian health ministry announced a programme that, in cooperation with the Netherlands, will organise for the joint purchase of treatments for 'rare' conditions - those affecting fewer than...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Industry Forecast
13
Pharmaceutical Market Forecast
13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belgium 2011-2019)
15
Healthcare Market Forecast
15
Table: Healthcare Expenditure Trends, Historical Data and Forecasts (Belgium 2011-2019)
17
Table: Government Healthcare Expenditure Trends, Historical Data and Forecasts (Belgium 2011-2019)
17
Table: Private Healthcare Expenditure Trends, Historical Data and Forecasts (Belgium 2011-2019)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belgium 2011-2019)
20
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belgium 2011-2019)
22
Generic Drug Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Belgium 2011-2019)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belgium 2011-2019)
27
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Belgium 2013-2019)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Belgium 2013-2019)
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
31
Economic Analysis
31
Table: Economic Activity (Belgium 2010-2019)
34
Industry Risk Reward Ratings
35
Western Europe Risk/Reward Index
35
Belgium Risk/Reward Index
39
Rewards
39
Risks
40
Market Overview
41
Industry Trends And Developments
42
Healthcare Sector
42
Table: Healthcare Resources
43
Table: Healthcare Personnel
44
Table: Healthcare Activity
44
Epidemiology
45
Public Health Developments
46
Health Insurance
47
Healthcare Financing
48
Research And Development
49
Clinical Trials
51
Regulatory Development
53
Regulatory Developments
56
Intellectual Property Issues
57
Pricing Regime
57
Reimbursement Regime
59
Table: Reimbursements by Category, 2009
61
Table: Price Build-Up for OTC Medicines
63
Competitive Landscape
64
Pharmaceutical Sector
64
Pharmaceutical Distribution
65
Pharmaceutical Retail Sector
65
Company Profile
67
GlaxoSmithKline (GSK)
67
Pfizer
70
Sanofi
73
Novartis
75
Merck & Co
77
UCB Pharma
79
Galapagos
83
Janssen Pharmaceutica
86
Omega Pharma
88
Solvay (Abbott)
91
Demographic Forecast
93
Table: Population Headline Indicators (Belgium 1990-2025)
94
Table: Key Population Ratios (Belgium 1990-2025)
94
Table: Urban/Rural Population & Life Expectancy (Belgium 1990-2025)
95
Table: Population By Age Group (Belgium 1990-2025)
95
Table: Population By Age Group % (Belgium 1990-2025)
96
Glossary
98
Methodology
100
Pharmaceutical Expenditure Forecast Model
100
Healthcare Expenditure Forecast Model
100
Notes On Methodology
101
Risk/Reward Index Methodology
102
Index Overview
103
Table: Pharmaceutical Risk/Reward Index Indicators
103
Indicator Weightings
104

The Belgium Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belgium Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belgium pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Belgium, to test other views - a key input for successful budgeting and strategic business planning in the Belgian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Belgian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Belgium.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc